Are Cyclin‐Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?

This letter to the editor remarks on recently reported results of the PALBONET study and describes reasons why it may be too early to eliminate CDK4/6 inhibitors as an option for the treatment of neuroendocrine...